Ascendis Pharma A/S  

(Public, NASDAQ:ASND)   Watch this stock  
Find more results for ASND
+0.14 (0.39%)
After Hours: 36.07 -0.02 (-0.04%)
Oct 17, 4:11PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.90 - 36.29
52 week 17.15 - 42.00
Open 35.90
Vol / Avg. 41,436.00/309,965.00
Mkt cap 1.31B
P/E     -
Div/yield     -
EPS -3.51
Shares 36.37M
Beta     -
Inst. own 65%
Sep 12, 2017
Ascendis Pharma A/S at Morgan Stanley Healthcare Conference
Sep 6, 2017
Ascendis Pharma A/S at Wells Fargo Healthcare Conference
Aug 18, 2017
Q2 2017 Ascendis Pharma A/S Earnings Call - Webcast
Aug 15, 2017
Ascendis Pharma A/S at Wedbush PacGrow Healthcare Conference
Aug 1, 2017
Ascendis Pharma A/S at Wells Fargo Boston Biotech Corporate Access Day
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -6915.77% -1487.30%
Operating margin -5555.63% -1583.15%
EBITD margin - -1568.45%
Return on average assets -78.16% -42.57%
Return on average equity -87.57% -46.14%
Employees 101 -
CDP Score - -


Tuborg Boulevard 5

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.

Officers and directors

Michael Wolff Jensen Chairman of the Board, Senior Vice President, General Counsel
Age: 42
Bio & Compensation  - Reuters
Jan Moeller Mikkelsen President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Scott T. Smith Chief Financial Officer, Senior Vice President
Bio & Compensation  - Reuters
Lotte Soenderbjerg Senior Vice President, Chief Administrative Officer
Age: 53
Bio & Compensation  - Reuters
Harald Rau Senior Vice President, Chief Scientific Officer
Age: 45
Bio & Compensation  - Reuters
Martin D. Auster M.D. Senior Vice President, Chief Business Officer
Age: 39
Bio & Compensation  - Reuters
Flemming Steen Jensen Senior Vice President, Product Supply
Age: 55
Bio & Compensation  - Reuters
Grethe Rasmussen Ph.D. Senior Vice President, Product Development
Age: 52
Bio & Compensation  - Reuters
Kennett Sprogoee Ph.D. Senior Vice President, Product Innovation
Age: 37
Bio & Compensation  - Reuters
Peter Rasmussen Vice President, Finance and Principal Financial and Accounting Officer
Age: 46
Bio & Compensation  - Reuters